Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Части II-V

Достижения в лечении онкологических заболеваний привели к повышению выживаемости больных со злокачественными новообразованиями. В то же время противоопухолевая терапия сопряжена с риском развития побочных эффектов, среди которых сердечно-сосудистые осложнения занимают лидирующие позиции. Дисфункция левого желудочка и сердечная недостаточность, артериальная гипертония, ишемия миокарда, нарушения ритма сердца, тромбоэмболии и другие сердечно-сосудистые осложнения могут препятствовать проведению жизненно важной противоопухолевой терапии, снижать выживаемость и качество жизни больных. В представленном руководстве отражены диагностические и терапевтические подходы к ведению больных онкологического профиля, получающих потенциально кардиотоксичную противоопухолевую терапию. Вторая часть руководства посвящена вопросам диагностики, профилактики и лечения ишемической болезни сердца, артериальной гипертонии, нарушений ритма и проводимости сердца и легочной артериальной гипертензии, связанных с противоопухолевой терапией.

кардиотоксичность, химиотерапия, ишемическая болезнь сердца, артериальная гипертония, нарушения ритма сердца, легочная артериальная гипертензия, диагностика, профилактика, лечение

1. Чазова И.Е., Тюляндин С.А., Виценя М.В. и др. Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Часть I. Системные гипертензии. 2017; 14 (3): 6-20.

2. Herrmann J, Lerman A. Vascular toxicities of cancer therapies. In: Clinical Cardio-oncology. Elsevier 2016; p. 163-84.

3. Polk A, Vistisen K, Vaage-Nilsen M. et al. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014; 15: 47.

4. De Forni M, Bugat R, Sorbette F. et al. Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases. Bull Cancer 1990; 77 (5): 429-38.

5. Südhoff T, Enderle M.D, Pahlke M. et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004; 15 (4): 661-4.

6. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Int Med J 2010; 40 (4): 303-7.

7. Grunwald M.R, Howie L, Diaz L.A Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol 2012; 30 (2): e11-e14.

8. Smith S.A, Auseon A.J. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin 2013; 9 (2): 233-42.

9. Cerny J, Hassan A, Smith C. et al. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer 2009; 8 (1): 55-8.

10. Ambrosy A.P, Kunz P.L, Fisher G.A. et al. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol 2012; 110 (11): 1623-6.

11. Boyle J.J, Wilson B, Bicknell R. et al. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol 2000; 192 (2): 234-42.

12. Coward J, Maisey N, Cunningham D. The effects of capecitabine in Raynaud’s disease: a case report. Ann Oncol 2005; 16 (5): 835-6.

13. Jensen S.A, Sorensen J.B. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58 (4): 487-93.

14. Polk A, Vaage-Nilsen M, Vistisen K. et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013; 39 (8): 974-84.

15. Rowinsky E.K, McGuire W.P, Guarnieri T. et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9 (9): 1704-12.

16. Schrader C, Keussen C, Bewig B. et al. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res 2005; 10 (11): 498-501.

17. Shah K, Gupta S, Ghosh J et al. Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature. J Cancer Res Ther 2012; 8 (3): 442-4.

18. Berliner S, Rahima M, Sidi Y. et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990; 8 (6): 583-6.

19. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anti Cancer Drugs 2008; 19 (9): 927-9.

20. Karabay K.O, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol 2014; 26 (2): E18-E20.

21. Togna G.I, Togna A.R, Franconi M. et al. Cisplatin triggers platelet activation. Thromb Res 2000; 99 (5): 503-9.

22. Dieckmann K.P, Gerl A, Witt J. et al. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 2010; 21 (8): 1607-11.

23. Ito D, Shiraishi J, Nakamura T. et al. Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart Vessels 2012; 27 (6): 634-8.

24. Meinardi M.T, Gietema J.A, van der Graaf W.T. et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18 (8): 1725-32.

25. Huddart R.A, Norman A, Shahidi M. et al. Cardiovascular disease as a long-term complication of treat-ment for testicular cancer. J Clin Oncol 2003; 21 (8): 1513-23.

26. Haugnes H.S, Wethal T, Aass N. et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28 (30): 4649-57.

27. Feldman D.R, Schaffer W.L, Steingart R.M. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Cancer Netw 2012; 10 (4): 537-44.

28. Gietema J.A, Meinardi M.T, Messerschmidt J. et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355 (9209): 1075-6.

29. Nuver J, Smit A.J, Sleijfer D.T. et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40 (5): 701-6.

30. Oh J.H, Baum D.D, Pham S.et al. Long-term complications of platinum-based chemotherapy W.J. in testicular cancer survivors. Med Oncol 2007; 24 (2): 175-81.

31. Kachel D.L, Martin. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 1994; 268 (1): 42-6.

32. Gottdiener J.S, Appelbaum F.R, Ferrans V.J. et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141 (6): 758-63.

33. Katayama M, Imai Y, Hashimoto H. et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol 2009; 54 (2): 330-4.

34. Stefenelli T, Kuzmits R, Ulrich W. et al. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J 1988; 9 (5): 552-6.

35. Soultati A, Mountzios G, Avgerinou C. et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev 2012; 38 (5): 473-83.

36. Schwarzer S, Eber B, Greinix H. et al. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991; 12 (6): 748-50.

37. Doll D.C, List A.F, Greco F.A. et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105 (1): 48-51.

38. Samuels B.L, Vogelzang N.J, Kennedy B.J. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19 (3): 253-6.

39. Panella M, Ross J.E, Garvin K. et al. Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma. J Forensic Sci 2010; 55 (5): 1384-8.

40. Gallagher H, Carroll W.M, Dowd M. et al. The effects of vinblastine on endothelial cells. Endothelium 2008; 15 (1): 9-15.

41. Schutz F.A, Je Y, Azzi G.R et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011; 22 (6): 1404-12.

42. Ranpura V, Hapani S, Chuang J. et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49 (3): 287-97.

43. Chen X.L, Lei Y.H, Liu C.F. et al. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One 2013; 8 (6): e66721.

44. Choueiri T.K, Schutz F.A, Je Y. et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28 (13): 2280-5.

45. Qi W.X, Shen Z, Tang L.N. et al. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis. Crit Rev Oncol Hematol 2014; 92 (2): 71-82.

46. Kappers M.H, van Esch J.H, Sluiter W. et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010; 56 (4): 675-81.

47. Winnik S, Lohmann C, Siciliani G. et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis-implications for cardiovascular safety. Int J Cardiol 2013; 168 (3): 2453-61.

48. Kappers M.H, Smedts F.M, Horn T. et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011; 58 (2): 295-302.

49. Kappers M.H, de Beer V.J, Zhou Z. et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59 (1): 151-7.

50. Arima Y, Oshima S, Noda K. et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 2009; 54 (3): 512-5.

51. Porto I, Leo A, Miele L. et al. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 2010; 7 (8): 476-80.

52. Naib T, Steingart R.M, Chen C.L. Sorafenib-associated multivessel coronary artery vasospasm. Herz 2011; 36 (4): 348-51.

53. Franco T.H, Khan A, Joshi V. et al. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 2008; 4 (6): 1367-70.

54. Numico G, Sicuro M, Silvestris N et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol 2012; 30 (24): e218-e220.

55. Sen F, Yildiz I, Basaran M. et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J BUON 2013; 18 (3): 775-81.

56. Chintalgattu V, Rees M.L, Culver J.C. et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med 2013; 5 (187): 187ra69.

57. Van der Veldt A.A, de Boer M.P, Boven E. et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anti Cancer Drugs 2010; 21 (4): 439-46.

58. Pantaleo M.A, Mandrioli A, Saponara M. et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer 2012; 12: 231.

59. Ropert S, Vignaux O, Mir O, Goldwasser F. VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption. Invest New Drugs 2011; 29 (6): 1497-9.

60. Meyer T, Robles-Carrillo L, Robson T. et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009; 7 (1): 171-81.

61. Aichberger K.J, Herndlhofer S., Schernthaner G.H. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86 (7): 533-9.

62. Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012; 12 (5): 337-40.

63. Levato L, Cantaffa R, Kropp M.G. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol 2013; 90 (6): 531-2.

64. Cortes J.E, Kantarjian H, Shah N.P. et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367 (22): 2075-88.

65. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011; 86 (7): 610-1.

66. Coon E.A, Zalewski N.L, Hoffman E.M. et al. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol 2013; 88 (6): 534-5.

67. Breccia M, Colafigli G, Molica M. et al. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol 2015; 90 (5): E100-E101.

68. Chislock E.M, Ring C, Pendergast A.M. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A 2013; 110 (30): 12432-7.

69. Teragawa H, Hondo T, Amano H. et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996; 37 (6): 905-15.

70. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37 (4): 300-11.

71. Kruit W.H, Eggermont A.M, Stoter G. Interferon-alpha induced Raynaud’s syndrome. Ann Oncol 2000; 11 (11): 1501-2.

72. Al-Zahrani H, Gupta V, Minden M.D. et al. Vascular events associated with alpha interferon therapy. Leuk Lymphoma 2003; 44 (3): 471-5.

73. Thacker S.G, Zhao W, Smith C.K. et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012; 64 (9): 2975-85.

74. Lancellotti P, Nkomo V.T, Badano L. et al. European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14: 721-40.

75. Zamorano J.L, Lancellotti Р, Munoz D.R. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37: 2768-801.

76. Piccirillo J.F, Tierney R.M, Costas I. et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291 (20): 2441-7.

77. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. Кардиологич. вестн. 2015; 1: 3-31.

78. Colt J.S, Schwartz K, Graubard B.I. et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011; 22: 797-804.

79. Milan A, Puglisi E, Ferrari L. et al. Arterial hypertension and cancer. Int J Cancer 2014; 134: 2269-77.

80. Izzedine H, Ederhy S, Goldwasser.F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807-15.

81. Qi W.X, He A.N, Shen Z et al. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013; 76: 348-57.

82. Qi W.X, Lin F, Sun Y. et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a metaanalysis. Cancer Chemother Pharmacol 2013; 71: 431-9.

83. Ranpura V, Pulipati B, Chu D. et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23: 460-8.

84. Li Y, Li S, Zhu Y. et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2014; 16 (3): 177-85.

85. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48: 9-17.

86. Qi W.X, Shen Z, Lin F. et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013; 75: 919-30.

87. Wang Z, Xu J, Nie W. et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2014; 70: 225-31.

88. Qi W.X, Fu S, Zhang Q. et al. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis. J Cancer Res Ther 2016; 12 (2): 775-81.

89. Qi W.X, Shen Z, Tang L.N et al. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin Drug Invest 2014; 34 (4): 231-40.

90. Wicki A, Hermann F, Prкtre V. et al. Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study. Oncol Res Treat 2014; 37: 230-6.

91. Hamnvik O.P, Choueiri T.K, Turchin A. et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121: 311-9.

92. Tomita Y, Uemura H, Fujimoto H et al. Japan Axitinib Phase II Study Group. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 2011; 47: 2592-602.

93. Small H.Y, Montezano A.C, Rios F.J.et al. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 2014; 30: 534-43.

94. Mourad J.J, Des Guetz G, Debbabi H. et al. Blood pressure rise following angiogenesis inhibition bybevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927-34.

95. Facemire C.S, Nixon A.B, Griffiths R.et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54: 652-8.

96. Ciuffetti G, Schillaci G, Innocente S. et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003; 21: 2297-303.

97. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008; 266 (1): 37-52.

98. Eremina V, Jefferson J.A, Kowalewska J. et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-36.

99. Scartozzi M, Galizia E, Chiorrini S. et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20 (2): 227-30.

100. Rini B.I, Cohen D.P, Lu D.R. et al. Hypertension as a biomarker of efficacy in patients with sunitinib.J Natl Cancer Inst 2011; 103 (9): 763-73.

101. De Souza V.B, Silva E.N, Ribeiro L. et al. Hypertension in Patients with Cancer. Arq Bras Cardiol 2015; 104 (3): 246-52.

102. Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.

103. Maitland M.L, Bakris G.L, Black H.R. et al. Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.

104. Herrmann J, Yang E.H, Iliescu C.A. et al. Vascular Toxicities of Cancer Therapies The Old and the New - An Evolving Avenue. Circulation 2016; 133: 1272-89.

105. Copur M.S, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151-6.

106. Nazer B, Humphreys B.D, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687-91.

107. McKay R.R, Rodriguez G.E, Lin X. et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21 (11): 2471-9.

108. Oliver J.J, Melville V.P, Webb D.J. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006; 48: 622-7.

109. Ewer M.S, Ewer S.M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010; 7: 564-75.

110. Yeh E.T, Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-47.

111. Tamargo J, Caballero R, Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015; 38: 129-52.

112. Soignet S.L, Frankel S.R, Douer D. et al. United States multicenter study of arsenic trioxide in relapsedacute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-60.

113. Lenihan D.J, Kowey P.R. Overview and management of cardiac adverse events associatedwith tyrosine kinase inhibitors. Oncologist 2013; 18: 900-8.

114. Shah R.R, Morganroth J, Shah D.R. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013; 36: 295-316.

115. Strevel E.L, Ing D.J, Siu L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007; 25: 3362-71.

116. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillationin cancer. J Am Coll Cardiol 2014; 63: 945-53.

117. Priori S.G, Blomstrom-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventriculararrhythmias and the prevention of sudden cardiac death: the Task Forcefor the Management of Patients with Ventricular Arrhythmias and the Preventionof Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsedby: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793-867.

118. Al-Khatib S.M, LaPointe N.M, Kramer J.M. et al. What clinicians should knowabout the QT interval. JAMA 2003; 289: 2120-7.

119. Bates S.E, Rosing D.R, Fojo T. et al. Challenges of evaluating the cardiaceffects of anticancer agents. Clin Cancer Res 2006; 12: 3871-4.

120. Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrialfibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962.

121. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-507.

122. Larsen T.B, Nielsen P.B, Skjoth F et al. Non-vitamin K antagonistoral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One 2014; 9 (12): e114445.

123. Limsuwan A, Pakakasama S, Rochanawutanon M et al. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology 2006; 105: 188-94.

124. Rasheed W, Flaim B, Seymour J.F. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009; 33: 861-4.

125. Mattei D, Feola M, Orzan F. et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43: 967-8.

126. Montani D, Bergot E, Günther S.et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-37.

127. Dumitrescu D, Seck C, ten Freyhaus H. et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 38: 218-20.

128. Guignabert C, Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J 2013; 41: 3-4.

129. Galie N, Humbert M, Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119.

130. Simonneau G, Gatzoulis M.A, Adatia I et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25): 34-41.

131. Ranchoux B, Gunther S, Quarck R et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 2015; 185: 356-71.

132. Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Тер. архив. 2014; 9: 4-23.